Loading...
•
Dec 31, 2023
10X Genomics Q4 2023 Earnings Report
10X Genomics reported an 18% increase in revenue compared to Q4 2022, driven by higher spatial instruments and consumables sales, but experienced a decrease in gross margin due to product mix and an increased operating loss due to higher operating expenses.
Key Takeaways
10X Genomics reported Q4 2023 revenue of $184.0 million, an 18% increase year-over-year. The company's gross margin decreased to 63% due to product mix, and the operating loss widened to $55.2 million. The company launched preorders for Visium HD Spatial Gene Expression and Chromium GEM-X technology.
Q4 2023 revenue increased by 18% year-over-year to $184.0 million.
Gross margin decreased to 63% due to product mix.
Operating loss was $55.2 million, compared to $23.1 million in the prior year period.
Launched preorders for Visium HD Spatial Gene Expression and Chromium GEM-X technology.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
10x Genomics expects full year 2024 revenue to be in the range of $670 million to $690 million, representing 8% to 12% growth over full year 2023 revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...